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E-mail address: rosy.tirimacco@ﬂinders.edu.au (R.Objective: To determine the accuracy and appropriateness of capillary blood glucose testing in population
surveys.
Materials and methods: Capillary blood glucose using the Rochec ACCU-CHEK instrument and Advantage
11 Test Strips was compared to a laboratory instrument. Three independent cross-sectional risk factor
surveys (n = 1432) and baseline individuals from the Greater Green Triangle Diabetes Prevention Project
(n = 341) provided both fasting plasma and capillary blood glucose measurements. Accuracy of capillary
glucoses was assessed using the ISO 15197 standard. The median age of the participants was 71 years,
ranging from 25 to 84 years. There were 799 males and 974 females.
Results: Capillary glucose method had poorer precision at lower concentrations (CV: 9.50%, mean = 3.09
mmol/L, CV: 4.90%, mean = 16.78 mmol/L, n = 233 replicates). Individual discrepancies were seen across
the measuring range (2.8–19.9 mmol/L, n = 1773). In total, 94.5% of results fell within the minimum
acceptable accuracy standards. This was slightly short of the 95% of results required to meet the ISO
15197 standard. The prevalence of diabetes in the study population using glucose P7.0 mmol/L was
2.4% (95%CI 1.8–3.3%) according to fasting plasma glucose and 2.8% (2.1–3.8%) according to fasting cap-
illary glucose. The lower WHO-deﬁned cut-off of 6.1 mmol/L for capillary blood glucose testing gave a
prevalence of 10.7% (9.0–12.5%).
Conclusions: This study of matched capillary and plasma glucose results concludes that while it is appro-
priate to use fasting capillary glucose levels to determine the prevalence of diabetes in populations, it
should not be used to reliably diagnose diabetes in individuals.
 2009 International Journal of Diabetes Mellitus. Published by Elsevier Ltd.
Open access under CC BY-NC-ND license.1. Introduction every diagnosed case. Direct health care expenditure on diabetesCurrently, 240 million people around the world are living with
diabetes with predictions showing that it will increase by 58% to
380 million by 2025. Globally, diabetes is the fourth biggest cause
of death affecting countries of all income levels and a wide variety
of epidemiological proﬁles [1]. The American Diabetes Association
has reported that medical expenditure for patients with diagnosed
diabetes is, on average, up to three times higher than in patients
without diabetes [2].
National data indicates that Australia has many cases of diabe-
tes that have not been diagnosed, with one undiagnosed case forellitus. Published by Elsevier Ltd.
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Ofor Australia in 2004–2005 was $907 million, representing 2% of
the allocated recurrent health expenditure [3].
As the impact of diabetes on the total burden of disease in Aus-
tralia, along with the rest of the world is increasing, it is important
that we monitor the prevalence of the disease, to guide the imple-
mentation of health promotion interventions.
Cardiovascular risk factor surveys with anthropometric mea-
surements and venous plasma sampling are an expensive, but nec-
essary exercise to determine the prevalence of cardiovascular
disease within populations. In particular, venous plasma sampling
for biochemical tests is costly, and in rural areas, the transport of
blood to laboratories for analysis is problematic. Analytes such as
glucose have to be collected and processed in a timely fashion to
ensure accurate results.
Capillary blood glucose testing, using portable point of care de-
vices, may be an alternative to venous plasma samples, because
they are easier, less expensive overall, and less invasive to obtain.
If capillary blood glucose testing is to be used in public healthpen access under CC BY-NC-ND license.
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precise.
The technology of glucose meters has improved, and capillary
monitoring glucose testing is now also widely used in the home,
general practice and hospital settings to assess glycaemic control
and to conﬁrm hypoglycaemia. A glucose meter which converts
capillary blood results to plasma levels has been reported as being
reliable for individuals with normal glucose tolerance and for type
2 diabetes subjects [4]. Many studies have concluded that glucose
meters should not be used for diagnosis, only for self-monitoring
[5–7].
In clinical practice, plasma and capillary blood glucose values
are often used interchangeably, despite levels of glucose being
higher in plasma than in erythrocytes [8].
Standards are in place which relate to monitoring systems for
self-testing in managing diabetes, but these should apply to all
capillary glucose monitoring performed with glucose meters [9].
There is a clear distinction in objectives between an epidemio-
logical and a clinical diagnosis of diabetes. An epidemiological
diagnosis of diabetes is based on a fasting glucose or a glucose tol-
erance test, whereas a clinical diagnosis requires laboratory conﬁr-
mation if the patient has no symptoms. Accurate glucose testing is
required for epidemiological studies to ensure participants with
dysglycaemia can be reliably identiﬁed.
As part of a study to determine the level and prevalence of car-
diovascular risk factors in rural Australia, we evaluated the accu-
racy and appropriateness of capillary blood glucose in population
surveys.2 4 6 8 10 12 14 16 18 20 22
4
3
2
1
0
-1
-2
-3
-4
Plasma  and Capillary Glucose Mean
Pl
as
m
a 
G
lu
co
se
 m
in
us
 C
ap
ill
ar
y 
G
lu
co
se
Mean
0.0
-1.96 SD
-1.1
+1.96 SD
1.1
Fig. 1. Bland–Altman plot: difference between venous plasma laboratory glucose
and capillary blood glucose. Mean difference 0.015, 95%CI: 0.011–0.0414.2. Materials and methods
Three independent cross-sectional surveys (n = 1432, 41%) of
chronic disease risk factors and related health behaviour were per-
formed in the Greater Green Triangle (GGT) region of south eastern
Australia, in 2004–2006 [10]. Additional data was obtained during
the GGT Diabetes Prevention Project (n = 341) in 2004–2006 [11].
The median age of the participants was 71 years, ranging from 25
to 84 years. There were 799 males and 974 females. There were
16 (0.01%) participants with a body mass index (BMI) of <18, 386
(22%) with a BMI of 18–25, 669 (38%) with a BMI of 25–30, and
702 (40%) with a BMI of >30.
Health checks, including anthropometric measurements and
venous plasma sampling (fasting at least 10 h) were carried out
at survey sites by specially trained nurses. A fasting capillary blood
glucose and plasma glucose test was included in the health check.
The Roche ACCU-CHEK instrument and Advantage 11 Test
Strips (Roche Diagnostics, Sydney, Australia) were used to perform
the capillary blood capillary glucose tests. The test strip contains
the enzyme glucose dehydrogenase, which converts the glucose
in whole blood to gluconolactone. This reaction liberates an elec-
tron that reacts with a mediator generating a small current that
is read by the instrument.
Roche liquid internal quality control material (Levels 1 and 2)
was run each morning prior to commencing the health checks.
To check the linearity of the ACCU-CHEK 11 strips, we ran Roche
Diagnostics Glucose Monitoring Quality Assurance samples distrib-
uted through RCPA Chemical Pathology Quality Assurance
Programs.
The venous blood samples were centrifuged and the plasma fro-
zen at the ﬁeld survey sites before being transferred to the Flinders
Medical Centre Clinical Trials Laboratory. An Hitachi 917 clinical
chemistry analyser (Roche Diagnostics, Sydney, Australia), hexoki-
nase/glucose-6-phosphate dehydrogenase method was used to
measure plasma glucose. Samples from all health surveys were
processed by Flinders Medical Centre Clinical Trials Laboratory.Statistical analysis was performed using MedCalc version
10.0.2 and PASW Statistics version 17.0.3. The results of the paired
plasma and capillary blood glucose measurements were used for
statistical analysis. Mean (standard error, SE) and 95% conﬁdence
intervals, as well as percentages, are presented as necessary. Statis-
tically signiﬁcant differences in mean values were determined with
a two-sided paired t-test.
The Pearson correlation coefﬁcient (r) was determined by linear
regression. A Bland–Altman plot was constructed by plotting the
absolute differences between paired samples against the average
of these paired samples.
Agreement between methods was also assessed by Passing &
Bablok Regression.
Accuracy of capillary glucoses was assessed using the Interna-
tional Organisation for Standardisation (ISO) 15197 standard,
which states that 95% of the individual results for the glucose me-
ter shall fall within ±0.83 mmol/L of the results at glucose concen-
trations 64.1 and ±20% at glucose concentrations >4.1 mmol/L.
3. Results
Two levels of quality control were run each day that health
checks were performed. The glucose meter produced a CV of
9.50% for the Level 1 control (mean = 3.09 mmol/L, SD = 0.29
mmol/L, n = 233) and a CV of 4.90% for the level 2 control
(mean = 16.78 mmol/L, SD = 0.82 mmol/L, n = 233). This shows that
the glucose meter is less precise (i.e. reproducible) at lower levels
of glucose concentration than higher concentrations.
Twelve Roche Diagnostics Glucose Monitoring Quality Assur-
ance samples were analysed by us and the result plotted against
median result of all participants of the RCPA Quality Assurance
program. The ACCU-CHEK method was shown to be linear for glu-
cose concentrations from 2.0 to 25.0 mmol/L (data not shown).
Fasting PoCT (1773 pairs) capillary and plasma laboratory
glucose results from the GGT data were compared. No difference
was observed between the mean fasting plasma glucose (5.41
mmol/L, 95% CI: 5.37–5.46) and capillary glucose (5.40 mmol/L,
95% CI: 5.35–5.45).
Fig. 1 shows a Bland–Altman plot demonstrating the differences
between plasma glucose and capillary glucose for paired samples
plotted versus the mean of the plasma and capillary glucose for
each pair. The mean plasma glucose was 0.015 mmol/L (95% CI:
0.011 to 0.0414) lower than the mean capillary glucose. Although
the mean difference between plasma and capillary glucose is small,
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be seen across the measuring range (2.8–19.9 mmol/L).
The Passing & Bablok Regression Equation for the relationship
between plasma glucose and capillary glucose was y = 1.167x 
0.90 (Fig. 2). A strong correlation was observed between plasma
and capillary glucose, with a Pearson concordance correlation coef-
ﬁcient of 0.84 (95% CI: 0.83–0.85).
Overall, 94.5% of results fell within the minimum acceptable
accuracy standards, slightly short of the 95% of results needed to
meet standard requirements (Tables 1a and 1b). Forty six percent0 2 4 6 8 10 12 14 16 18 20
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Fig. 2. Passing and Bablok Regression: Capillary blood glucose = 1.167  Venous
plasma laboratory glucose  0.9 mmol/L.
Table 1a
Accuracy of capillary blood glucose results 64.1 mmol/L (n = 70).
n % of results
Accuracy of results for glucose 64.1 mmol/L
±0.3 mmol/L 6 8.6
±0.6 mmol/L 19 27.1
±0.8 mmol/L 38 54.3
±1.1 mmol/L 55 78.6
Table 1b
Accuracy of capillary blood glucose results >4.1 mmol/L (n = 1773).
n % of results
Accuracy of results for glucose >4.1 mmol/L
Within ± 5% 865 50.8
Within ± 10% 1369 80.4
Within ± 15% 1568 92.1
Within ± 20% 1638 96.2
Table 3
Agreement for the classiﬁcation of patients using the same fasting cut-off values for veno
Classiﬁcation Capillary blood glucose
Normoglycaemic Impaired fa
Venous plasma glucose
Normoglycaemic 1035 (84.5) 185 (15.1)
Impaired fasting glucose (5.6–6.9 mmol/L) 119 (25.4) 328 (69.9)
Diabetes (P7.0 mmol/L) 2 (2.5) 14 (17.7)
Total 1156 (65.2) 527 (29.7)of capillary glucose results 64.1 mmol/L, and 3.8% of results
>4.1 mmol/L, were inaccurate.
Table 2 shows the effect of patient characteristics on the capil-
lary blood glucose results compared to the plasma laboratory re-
sult. Statistically signiﬁcant differences were observed in the
mean results for participants >75 years of age, females and those
with a BMI of 18–24.9 and P30.
Table 3 shows that in normoglycaemic patients, there is an
84.5% concordance between capillary and plasma glucose. Overall,
185 patients displayed an impaired fasting capillary glucose and
would have undergone further testing to be classiﬁed as normogly-
caemic by venous plasma glucose. Capillary testing would have
incorrectly identiﬁed 121 patients as normoglycaemic when the
fasting plasma glucose identiﬁed them as having an impaired fast-
ing glucose or diabetes. Sixteen participants identiﬁed as having
diabetes by plasma glucose testing would not have been identiﬁed
with fasting capillary glucose testing.
If WHO-deﬁned values for diagnosis of diabetes are used (plas-
maP7.0 mmol/L, capillary bloodP6.1 mmol/L), concordance with
plasma glucose results is excellent, but 217 participants would
have been diagnosed with diabetes incorrectly and undergone fur-
ther testing (Table 4).
In separate analyses of Risk Factor Study data only (1432 indi-
viduals aged 25–74, weighted to the local population), the preva-
lence of diabetes using glucose P7.0 mmol/L was 2.4% (95% CI
1.8–3.3%) according to fasting plasma glucose and 2.8% (2.1–
3.8%) according to fasting capillary glucose. The lower WHO-de-
ﬁned cut-off of 6.1 mmol/L for capillary glucose testing gave a
prevalence of 10.7% (9.0–12.5%). Prevalence ﬁgures within the pop-
ulation are higher when a history of known diabetes is also
included.Table 2
Comparison of capillary blood glucose and venous plasma laboratory glucose
measurements [mean (SE)] by participant characteristic.
Characteristic Capillary blood glucose Plasma laboratory
glucose
n (%) Mean (SE) Mean (SE)
Age 25–44 256 (14) 5.04 (0.05) 5.04 (0.05)
45–54 459 (26) 5.31 (0.04) 5.29 (0.03)
55–64 498 (28) 5.46 (0.05) 5.47 (0.04)
65–74 441 (25) 5.64 (0.06) 5.66 (0.06)
>75 117 (7) 5.34 (0.07) 5.52 (0.09) **
Gender Male 799 (45) 5.53 (0.04) 5.52 (0.03)
Female 974 (55) 5.29 (0.03) 5.33 (0.03) *
BMI <18 16 (1) 5.19 (0.29) 5.35 (0.34)
18–24.9 386 (22%) 5.03 (0.06) 5.18 (0.05) **
25–29.9 669 (38) 5.30 (0.03) 5.32 (0.03)
P30 702 (40) 5.70 (0.04) 5.63 (0.04) **
Smoking Smoker 1622 (92) 5.40 (0.03) 5.42 (0.02)
Non-smoker 149 (8) 5.38 (0.07) 5.34 (0.06)
* p < 0.05.
** p < 0.01.
us plasma laboratory and capillary blood samples. % of total represented in brackets.
Total
sting glucose (5.6–6.9 mmol/L) Diabetes (P7.0 mmol/L)
5 (0.4) 1225 (69.1)
22 (4.7) 469 (26.5)
63 (79.7) 79 (4.5)
90 (5.1) 1773 (100)
Table 4
Utility for screening for diabetes. Criteria for diabetes classiﬁcation was capillary
blood P6.1 mmol/L, venous plasma P7.0 mmol/L.
PoCT
classiﬁcation
Capillary (%) Plasma classiﬁcation
agreement with
capillary
% Agreement
capillary with
plasma
Non-diabetes 1482 (83.6) 1477 (<7.0) 99.7
Diabetes 291 (16.4) 74 (P7.0) 25.4
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Results of this study show that although capillary and plasma
glucose measurements correlate well, they fall short of meeting
the ISO 15197 guidelines for minimum acceptable accuracy stan-
dards. Inaccuracies were predominantly in the low glucose range
(64.1 mmol/L) with almost 50% of results not falling within the
recommended ±0.83 mmol/L of plasma value. This is not surpris-
ing, as our study has shown poorer precision of capillary glucose
method at lower concentrations.
The differences observed between the mean capillary blood glu-
cose levels and mean plasma laboratory glucose levels for partici-
pants aged >75 years might be explained by decreased blood ﬂow
from impaired circulation in the ﬁnger tip, possibly resulting in a
poor capillary blood sample, which affects the accuracy of the
reading. A signiﬁcant difference between the mean values was also
observed for participants with a BMI of 18–24.9. There was a
marked difference between the mean values for participants with
a BMI of <18, however the small sample size for this group meant
it was not statistically signiﬁcant. However, these results are con-
sistent with a paper byWeinstein et al, who noted inaccuracies in a
glucose meter for patients with a low BMI [12].
Statistically signiﬁcant differences were also observed between
the mean capillary blood glucose levels and mean plasma labora-
tory glucose levels for female participants and participants with
a BMI > 30. The reasons for these differences are unclear; however,
the differences in these means were much smaller than those seen
for participants >75 years of age and those with a BMI of 18–24.9.
Current clinical practice generally uses plasma and capillary
blood glucoses interchangeably with a risk of clinical misinterpre-
tation. In human blood, glucose, like water, is distributed between
erythrocytes and plasma. The amount of glucose per unit of water
mass is the same throughout the sample. Because the water con-
centration in plasma is higher than in capillary blood, the concen-
tration of glucose is also higher in plasma than in erythrocytes.
IFCC Scientiﬁc Division Working Group on selective electrodes
and point-of-care testing have recommended that a constant factor
of 1.11 be used to convert the concentration of capillary blood glu-
cose to plasma glucose to reduce clinical misinterpretations when
using point of care devices to measure glucose. The calculated re-
sult equals the concentration of glucose in plasma when the hae-
matocrit and water concentrations are normal [8]. In public
health screening or in epidemiological surveys, the subject’s hae-
matocrit concentration is not known, and it would be more appro-
priate to use capillary blood speciﬁc cut-off points.
From this study, it can be concluded that it is acceptable to use
fasting capillary glucose levels to determine the prevalence of
diabetes in populations. Although the capillary glucose testing mis-classiﬁed a large number of individual patients, the overall preva-
lence of diabetes in the population using the capillary glucose cut-
off of P7.0 mmol/L was similar to the prevalence determined by
the plasma glucose cut-off of P7.0 mmol/L. Using the lower
WHO-deﬁned cut-off of 6.1 mmol/L for capillary testing resulted,
as expected, in a signiﬁcant rise in the prevalence of diabetes in
the population.
Fasting capillary glucose method is not suitable to reliably iden-
tify individuals with impaired fasting glucose or diabetes. Nurses
performing risk factor surveys using capillary blood glucose results
should tell patients with a result <6.1 mmol/L that they probably
do not have diabetes (unless displaying clinical symptoms). Pa-
tients with results P6.1 mmol/L should be told that their result
was inconclusive and that they should visit their doctor for a re-
peat fasting and 2 h post-glucose load plasma glucose levels before
any diagnosis can be made.
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